BrightGene announced that the company has decided to terminate the issuance of A-shares to specific targets for the year 2024 and will apply to the Shanghai Stock Exchange to withdraw the relevant documents. This termination is based on a comprehensive consideration of the current market environment, the company's actual situation, and development plans, aiming to protect the interests of all shareholders, especially those of small and medium-sized investors